Trial NCT04368728
Publication Polack FP,N Engl J Med,2020
Primary outcome on the report: Safety: The primary end points of this trial were solicited, specific local or systemic adverse events and use of antipyretic or pain medication within 7 days after the receipt of each dose … and unsolicited adverse events … through 1 month after the second dose and unsolicited serious adverse events through 6 months after the second dose. Efficacy: The first primary end point was the efficacy of BNT162b2 against confirmed Covid-19 with onset at least 7 days after the second dose in participants who had been without serologic or virologic evidence of SARS-CoV-2 infection up to 7 days after the second dose.